Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05215574 · ClinicalTrials.gov registry record · Phase 1

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by NGM Biopharmaceuticals.

Active
Registry status
Phase 1
Development phase
130
Enrollment target
9
Study locations

NCT05215574 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by NGM Biopharmaceuticals. The registered enrollment target is 130 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05215574, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by NGM Biopharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
130 participants
Enrollment target
9
Study locations

Study Summary

Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer Pancreatic Cancer Gastric Cancer Cervical Cancer Esophageal Cancer Colorectal Carcinoma Squamous Cell Carcinoma of Head and Neck Endocervical Cancer Bladder Urothelial Cancer

Interventions

  • DRUG NGM831
  • DRUG NGM831 plus pembrolizumab (KEYTRUDA®)
  • DRUG NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)

Study Locations (9)

Florida

  • NGM Clinical Study Site - Sarasota
  • NGM Clinical Study Site - Tampa

Texas

  • NGM Clinical Study Site - Austin
  • NGM Clinical Study Site - Houston

Arizona

  • NGM Clinical Study Site - Gilbert

California

  • NGM Clinical Study Site - Los Angeles

Michigan

  • NGM Clinical Study Site - Grand Rapids

New York

  • NGM Clinical Study Site - New York

Oklahoma

  • NGM Clinical Study Site - Oklahoma City

Trial Details

FieldValue
Enrollment Target 130 participants
Start Date 2022-03-31
Est. Completion 2026-03
Phase Phase 1

Sponsor

NGM Biopharmaceuticals

18 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05215574

The ClinicalTrials.gov registry entry for NCT05215574 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which NGM831 is the first listed.

NCT05215574 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Florida, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT05215574 about?

NCT05215574 is a clinical study titled "Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors". Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

What is the current status of trial NCT05215574?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2022-03-31. Estimated completion is 2026-03.

What conditions does trial NCT05215574 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Gastric Cancer, Cervical Cancer.

What interventions are being tested in trial NCT05215574?

The interventions under investigation include: NGM831 (DRUG), NGM831 plus pembrolizumab (KEYTRUDA®) (DRUG), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®) (DRUG).

Who is sponsoring clinical trial NCT05215574?

This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05215574 being conducted?

This trial has 9 study locations across Arizona, California, Florida, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.